Toxicity of hyperglycaemia in type 2 diabetes

Diabetes/Metabolism Reviews

Volumn 14, Issue SUPPL. 1, 1998, Pages

  Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Hyperglycaemia; Toxicity; Type 2 diabetes

Indexed keywords

GLUCOSE; HEXOSAMINE;

CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEXOSAMINES; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE;

EID: 0031740402     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199809)14:1+3.0.CO;2-7     Document Type: Conference Paper

References (38)

1. Yki-Järvinen H: Glucose toxicity. Endocr Rev 13: 415-431, 1992.
2. Uusitupa MIJ, Niskanen KL, Siitonen O, Voutilainen E, and Pyörälä K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and nondiabetic subjects. Diabetologia 36: 1175-1184, 1993.
3. Andersson DK, and Svardsudd K: Long-term glycemic control relates to mortality in Type II diabetes. Diabetes Care 18: 1534-1543, 1995.
4. Lehto S, Rönnemaa T, Pyörälä K, and Laakso M: Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 27: 63-68, 1996.
5. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, and Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46: 1354-1359, 1997.
6. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, and Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44: 1303-1309, 1995.
7. Kuusisto J, Mykkänen L, Pyörälä K, and Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960-967, 1995.
8. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, and Holle R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39: 1540-1545, 1996.
9. Alberti KGMM, and McGarry JD: Macrovascular disease in diabetes. Diabetologia 40 (Suppl 2) S108-S160, 1997.
10. Kawamura M, Heinecke JW, and Chait A: Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94: 771-778, 1994.
11. Tesfamariam B, Brown ML, and Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87: 1643-1648, 1991.
12. Mäkimattila S, Virkamäki A, Groop P-H, Cockcroft J, Utriainen T, Fagerudd J, and Yki-Järvinen H: Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94: 1276-1282, 1996.
13. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, and Welin L, on behalf of the DIGAMI study group: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57-65, 1988.
14. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock, JP, Emanuele NV, Levin SR, Pacold I, Sook Lee H, and the VACSDM Group: Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs cooperative study on glycemic control and complications in Type II diabetes. Arch Intern Med 157: 181-188, 1997.
15. Rossetti L, Giaccari A, and DeFronzo RA: Glucose toxicity. Diabetes Care 13: 610-630, 1990.
16. Klein R, Klein BEK, and Moss SE: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 124: 90-96, 1996.
17. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
18. Yki-Järvinen H, and Koivisto VA: Natural course of insulin resistance in Type 1 diabetes. N Engl J Med 315: 224-230, 1986.
19. Lillioja S, Mott, DM, Howard BV, Bennett PH, Yki-Järvinen H, Freymond BL, Nyomba F, Zurlo B, Swinburn B, and Bogardus C: Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318: 1217-1225, 1988.
20. Sakul H, Pratley R, Cardon L, Ravussin E, Mott D, and Bogardus C: Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians. Am J Hum Genet 60: 651-656, 1997.
21. Vuorinen-Markkola H, Koivisto VA, and Yki-Järvinen H: Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of Type 1 diabetic patients. Diabetes 41: 571-580, 1992.
22. Yki-Järvinen H, Helve E, and Koivisto VA: Hyperglycemia decreases glucose uptake in Type 1 diabetes. Diabetes 36: 892-896, 1987.
23. DeFronzo RA, Gunnarson R, Björkman O, Olsson M, and Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (Type II) diabetes mellitus. J Clin Invest 76: 149-155, 1985.
24. Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Rönnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvelä O, Cobelli C, and Yki-Järvinen H: Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 100: 777-785, 1997.
25. Yki-Järvinen H, Sahlin K, Ren JM, and Koivisto VA: Localization of the rate-limiting defect for glucose disposal in skeletal muscle of insulin-resistant Type 1 diabetic patients. Diabetes 39: 157-167, 1990.
26. Mäkimattila S, Virkamäki A, Malmström R, Utriainen T, and Yki-Järvinen H: Insulin resistance in Type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab 81: 707-712, 1996.
27. Utriainen T, Malmström R, Mäkimattila S, and Yki-Järvinen H: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 38: 555-564, 1995.
28. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly T, and Gerich J: Contribution of abnormal muscle and liver metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990.
29. Zierath JR, Galuska D, Nolte LA, Thörne A, Smedegaard Kristensen J, and Wallberg-Henriksson H: Effect of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance. Diabetologia 37: 270-277, 1994.
30. Marshall S, Bacote V, and Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system: role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266: 4706-4712, 1991.
31. Kornfeld R: Studies on L-glutamine D-fructose 6-phosphate amidotransferase. I. Feedback inhibition by uridine diphosphate-N-acetylglucosamine. J Biol Chem 242: 3135-3141, 1967.
32. Hebert LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu J-S, Baron AD, and McClain DA: Overexpression of glutamine:fructose-6-phosphate amidotransferase in skeletal muscle of transgenic mice leads to insulin resistance. J Clin Invest 98: 930-936, 1996.
33. Robinson KA, Weinstein ML, Lindenmayer GE, and Buse MG: Effects of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. Diabetes 44:1438-1446, 1995.
34. Rossetti L, Hawkins M, Gindi J, and Barzilai N: In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 96: 132-140, 1995.
35. Yki-Järvinen H, Daniels MC, Virkamäki A, Mäkimattila S, DeFronzo RA, and McClain D: Increased glutamine:fructose-6-phosphate amido-transferase activity in skeletal muscle of patients with NIDDM. Diabetes 45: 302-307, 1996.
36. Haltiwanger RS, Kelly WG, Roquemore EP, Blomberg MA, Dong LL-Y, Kreppel L, Chou T-Y, and Hart GW: Glycosylation of nuclear and cytoplasmic proteins is ubiquitous and dynamic. Biochem Soc Trans 20: 264-269, 1992.
37. Hart GW: Glycosylation. Curr Opin Cell Biol 4: 1017-1023, 1992.
38. Baron AD, Zhu J-S, Zhu J-H, Weldon H, Maianu L, and Garvey, WT: Glucosamine induces insulin resistance in vivo by affecting GLUT4 translocation in skeletal muscle. J Clin Invest 96: 2792-2801, 1995.